πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,413 results for β€œChinese” Clear

  1. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  2. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  3. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  4. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. IBD0333

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    MTD

    phase 2 mab active

    1 trial

  6. IBI363

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Iguratimod

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    ITP

    phase 2 small molecule active

    1 trial

  8. Indigo naturalis ointment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Psoriasis

    phase 2 small molecule completed

    1 trial

  9. Induction Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

    phase 2 small molecule active

    1 trial

  10. Induction therapy of GP(Pomalidomide+ObinutuzumabοΌ‰

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  11. Injection of IAH0968+Gemcitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HER2 Gene Mutation

    phase 2 other active

    1 trial

  12. Inotuzumab ozogamicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  14. Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Cell Carcinoma (RCC)

    phase 2 small molecule active

    1 trial

  15. Intraventricular Pemetrexed

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leptomeningeal Metastasis

    phase 2 small molecule active

    1 trial

  16. Intravitreal injection of KH902

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neovascular Age-related Macular Degeneration

    phase 2 mab completed

    1 trial

  17. Iparomlimab and Tuvonralimab Injection (QL1706)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  18. Iparomlimab/Tuvonralimab

    Chinese University of Hong Kong

    LOCALLY ADVANCED CERVICAL CANCERS

    phase 2 small molecule active

    1 trial

  19. Irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Irinotecan Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  21. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Ivosidenib, Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule active

    1 trial

  23. JDB0131

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Drug-resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  24. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources